Company: HSDTW
Filing Date: 2025-10-02
Form Type: PRE 14A
Source: 0001104659-25-096093
Chunk: 69

Company: Solana Co
Filing Date: 2025-10-02
Form: PRE 14A
Chunk 69
---
 as applicable. As such, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must comply with the additional requirements of Rule 14a-19 under the Exchange Act including providing notice that sets forth the information required by not earlier than the close of business on December 22, 2025 and not later than the close of business on January 21, 2026. We reserve the right to reject, rule out of order or take other appropriate action with respect to any proposal that does not comply with the foregoing and other applicable requirements. Solicitation by Board; Expenses The Board is sending you this proxy statement in connection with the solicitation of proxies for use at the Special Meeting. We have engaged [ ] to assist in the solicitation of proxies and provide related advice and informational support, for a services fee and the reimbursement of customary disbursements, which are not expected to exceed $[ ] in total. The Company’s directors, officers and regular employees may solicit proxies personally, telephonically, electronically or by other means of communication, but they will not receive any additional compensation for these services. The Company will pay the cost of preparing, assembling, and mailing the proxy materials. The Company has requested brokers, banks and other nominees to send the proxy materials to, and to obtain proxies from, the beneficial owners and the Company will reimburse such record holders for their reasonable expenses in doing so. Your cooperation in giving this matter your immediate attention and in voting your proxies promptly is appreciated. By Order of the Board of Directors, Jeffrey S. Mathiesen
Chief Financial Officer, Treasurer and Secretary
[ ], 2025 44 TABLE OF CONTENTS APPENDIX A AMENDMENT 3
TO
2022 EQUITY INCENTIVE PLAN RECITALS A. Helius Medical Technologies, Inc., a Delaware corporation (the “ Company ”) sponsors the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended (the “ Plan ”). B. The Plan is amended by this Amendment 3 (this “ Third Amendment ”) in the following respects, effective from and after the date this Third Amendment is approved by the stockholders of Helius Medical Technologies, Inc., in accordance with Section 7(b) of the Plan. Following such effective date, any reference to the “Plan” shall mean the Plan, as amended on June 27, 2024, May 23, 2025 and by this Third Amendment. All capitalized terms used but not